Companies in #Cardiovascular Disease
Found 3 companies operating in this sector.
Atrium Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeted therapeutics for cardiovascular diseases. Lead program ATR 1072 is being advanced for PRKAG2 syndrome, a rare genetic cardiac condition.
Osanni Bio
PrivateOsanni Bio is a San Francisco-based biotechnology company building a pipeline of therapeutics for ophthalmology and cardiology indications. The company raised $190M in 2026 to advance its portfolio of small-molecule and biologic candidates addressing high-prevalence vision and cardiovascular diseases.
Tectonic Therapeutic is a clinical-stage biotechnology company developing a pipeline of conformationally-stabilized G-protein-coupled receptor (GPCR) antibodies and other biologics, with an initial focus on cardiovascular disease. Its lead program, TX000045, is being developed for Hereditary Hemorrhagic Telangiectasia (HHT) and other vascular malformations driven by abnormal TGF-beta signaling. The company's platform is designed to enable antibody-based targeting of GPCRs and other traditionally difficult targets.